# Natalizumab Treatment Satisfaction in the TONiC-MS Study
Keywords: Natalizumab, TONiC-MS Study, intravenous, subcutaneous, multiple sclerosis, treatment satisfaction, adverse events

> This page provides information about the TONiC-MS study, focusing on patient satisfaction when switching from intravenous (IV) to subcutaneous (SC) administration of Natalizumab for multiple sclerosis treatment.

## Details
- [TYSABRI SC](#): Overview of the subcutaneous formulation of TYSABRI and its benefits for patients.
- [TONiC-MS Study](#): Insights into the TONiC-MS study, evaluating treatment satisfaction for patients transitioning from IV to SC administration.
- [The EASIER Study](#): Details on the EASIER study, focusing on real-world evidence and patient outcomes.
- [SC vs IV Real-World Efficacy](#): Comparison of subcutaneous and intravenous formulations of Natalizumab in real-world settings.
- [Adverse Event Reporting](#): Instructions for reporting adverse events in the UK and Ireland, including contact details for Biogen.